Manufacturer record

Legen Healthcare: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

5 batches manufactured by Legen Healthcare (Himachal Pradesh) were declared Not of Standard Quality between January 2020 and August 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

5 records linked to Legen Healthcare in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
5Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Jan 2020 to Aug 2024

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

5
NSQ batches since 2020
4
Products affected
Dissolution
Most common failure
Aug 2024
Latest alert

Flagged batches per year

2020 · 12021 · 12024 · 3

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Rifmin 550 (Rifaximin Tablets 550 mg) TX-17798Mfg 2024-02 · Exp 2026-01 Dissolution & WaterDissolution CDL KolkataCDSCO lab Aug 2024
Rifaximin Tablets 200 mg (Foxigen-200) TX-17329Mfg 2023-05 · Exp 2025-04 DissolutionDissolution CDL KolkataCDSCO lab Mar 2024
Rifaximin Tablets (Faxigen-550) TX-17503Mfg 2023-08 · Exp 2025-07 Water, Dissolution & AssayAssay CDL KolkataCDSCO lab Mar 2024
DIPHENHYDRAMINE HYDROCHLORIDE, AMMONIUM CHLORIDE, SODIUM CITRATE AND MENTHOL SRYUP LX-5435Mfg 2021-01 · Exp 2022-06 Assay of MentholAssay RDTL ChandigarhCDSCO lab May 2021
(Amoxycillin Dispersible Tablets IP 250 mg ) LBT-1578Mfg 2019-03 · Exp 2020-09 Uniformity of DispersionUniformity of weight/content RDTL ChandigarhState lab Jan 2020

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.